# A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

> **NCT05932290** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 514 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05932290
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-07-12
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932290, "A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05932290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*